Evogene (EVGN) Share-based Compensation (2013 - 2026)
Evogene (EVGN) posted Share-based Compensation of -$9000.0 for Q1 2026, down 105.81% sequentially from $155000.0 in Q4 2025, and down 103.78% YoY from $238000.0 in Q1 2025.
Evogene (EVGN) Share-based Compensation (2013 - 2026) Analysis & Trends
Evogene has reported Share-based Compensation for 14 years, with the latest figure at -$9000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 103.78% year-over-year to -$9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $407000.0 (down 65.33% YoY) and the FY2025 annual result came in at $654000.0, down 47.39% from the prior year.
- Share-based Compensation retreated to -$9000.0 in Q1 2026 per EVGN's latest filing, from $155000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $801000.0 in Q2 2023 and troughed at -$9000.0 in Q1 2026.
- A 5-year average of $304882.4 and a median of $291000.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation surged 738.46% in 2023, then slumped 103.78% in 2026.
- Over 5 years, Share-based Compensation stood at $291000.0 in 2022, then sank by 61.17% to $113000.0 in 2023, then soared by 132.74% to $263000.0 in 2024, then plunged by 41.06% to $155000.0 in 2025, then sank by 105.81% to -$9000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$9000.0, $155000.0, and $27000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,000.00 |
| Mar 31, 2026 | -9,000.00 |
| Dec 31, 2025 | 155,000.00 |
| Dec 31, 2025 | 155,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 234,000.00 |
| Jun 30, 2025 | 234,000.00 |
| Mar 31, 2025 | 238,000.00 |
| Mar 31, 2025 | 238,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Sep 30, 2024 | 362,000.00 |
| Sep 30, 2024 | 362,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Mar 31, 2024 | 539,000.00 |
| Mar 31, 2024 | 539,000.00 |
| Dec 31, 2023 | 113,000.00 |
| Dec 31, 2023 | 113,000.00 |